Kinetics of the immune response following pneumococcal PD conjugate vaccination

Area of Science:

• Immunology
• Vaccinology
• Pediatric Infectious Diseases

Background:

• Pneumococcal protein D conjugate vaccine is used for primary immunization in infants.
• Understanding the long-term immunogenicity and immune memory is crucial for vaccine efficacy.

Purpose of the Study:

• To evaluate the immunogenicity of pneumococcal protein D conjugate vaccine in infants.
• To assess antibody persistence and response to booster vaccination and subsequent natural exposure.

Main Methods:

• ELISA and Opsonophagocytic Activity (OPA) assays were used to measure antibody responses.
• Longitudinal study design tracking antibody levels from infancy to four years of age.
• Comparison between conjugate vaccine recipients, control groups, and response to plain polysaccharide vaccine.

Main Results:

• Primary vaccination induced variable ELISA and OPA responses across serotypes.
• Booster vaccination in the second year restored antibody levels, except for serotype 3.
• Antibody levels declined by age four but remained higher than in unvaccinated children, suggesting immune memory.
• Evidence of natural immunity development in control groups indicated exposure to pneumococci or cross-reacting bacteria.

Conclusions:

• Pneumococcal protein D conjugate vaccine elicits initial immune responses that are boosted by a second-year dose.
• While antibody levels wane, immune memory persists, offering protection beyond primary and booster vaccinations.
• Natural exposure contributes to immunity, particularly for certain pneumococcal serotypes.